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TGFβRIIb Mutations Trigger Aortic Aneurysm
Pathogenesis by Altering Transforming Growth
Factor β2 Signal Transduction
Katharine J. Bee, PhD; David C. Wilkes, PhD; Richard B. Devereux, MD;
Craig T. Basson, MD, PhD; Cathy J. Hatcher, PhD
Background—Thoracic aortic aneurysm (TAA) is a common progressive disorder involving gradual dilation of the ascending
and/or descending thoracic aorta that eventually leads to dissection or rupture. Nonsydromic TAA can occur as a genetically
triggered, familial disorder that is usually transmitted in a monogenic autosomal dominant fashion and is known as familial
TAA. Genetic analyses of families affected with TAA have identified several chromosomal loci, and further mapping of familial
TAA genes has highlighted disease-causing mutations in at least 4 genes: myosin heavy chain 11 (MYH11), α-smooth muscle
actin (ACTA2), and transforming growth factor β receptors I and II (TGFβRI and TGFβRII).
Methods and Results—We evaluated 100 probands to determine the mutation frequency in MYH11, ACTA2, TGFβRI, and
TGFβRII in an unbiased population of individuals with genetically mediated TAA. In this study, 9% of patients had a mutation
in one of the genes analyzed, 3% of patients had mutations in ACTA2, 3% in MYH11, 1% in TGFβRII, and no mutations
were found in TGFβRI. Additionally, we identified mutations in a 75 base pair alternatively spliced TGFβRII exon, exon 1a
that produces the TGFβRIIb isoform and accounted for 2% of patients with mutations. Our in vitro analyses indicate that the
TGFβRIIb activating mutations alter receptor function on TGFβ2 signaling.
Conclusions—We propose that TGFβRIIb expression is a regulatory mechanism for TGFβ2 signal transduction. Dysregulation
of the TGFβ2 signaling pathway, as a consequence of TGFβRIIb mutations, results in aortic aneurysm pathogenesis. (Circ

Cardiovasc Genet. 2012;5:621-629.)
Key Words: aneurysm ◼ aorta ◼ cardiovascular diseases ◼ genetics
◼ transforming growth factor-β pathway

T

horacic aortic aneurysm (TAA) is a common progressive
disorder involving gradual dilation of the ascending and
descending thoracic aorta that eventually leads to dissection or
rupture. TAAs are often clinically silent and unsuspected until
dissection or rupture occurs. The result is significant morbidity
and mortality despite advances in surgical and percutaneous
treatments for aortic disease. Although TAA is often a feature of
Mendelian complex connective tissue disorders such as Marfan
syndrome, Ehlers-Danlos syndrome type IV, or Loeys-Dietz
syndrome (LDS), most TAAs occur as isolated nonsyndromic
disorders. Nonsydromic TAAs can also be a familial disorder
that is usually transmitted in a monogenic autosomal dominant
fashion. These genetically triggered TAAs account for ≈20%
of TAAs.1–6 Genetic analyses of familial TAA (FTAA) have
identified several chromosomal loci. Further mapping of FTAA
genes has highlighted disease-causing mutations in at least 4
genes: myosin heavy chain 11 (MYH11), α-smooth muscle
actin (ACTA2), and transforming growth factor β receptors I
and II (TGFβRI and TGFβRII).7–10 Recent studies have also
identified mutations in 2 novel genes, MYLK and SMAD3, that
are linked to syndromic aortic aneurysms and dissections.11,12

Also, disease genes remain to be determined at additional loci
such as AAT1 (also known as FAA1) on chromosome 11q2313
and AAT2 (also known as TAAD1) on chromosome 5q13.14

Clinical Perspective on p 629
Because of the identification of TGFβRI and TGFβRII
mutations in aortic aneurysm syndromes such as LDS, considerable attention has been devoted to the role that TGFβ
may play in FTAA pathogenesis. The TGFβ receptor superfamily is composed of cytokines that control numerous
diverse cellular processes including cell proliferation, differentiation, angiogenesis, and modification of the extracellular matrix.13–16 Canonical TGFβ signaling is initiated when a
TGFβ ligand binds to TGFβRII, resulting in the recruitment
of TGFβRI. On ligand binding, TGFβRII activates TGFβRI
via transphosphorylation of its kinase domain and propagates downstream signaling actions. Receptor-regulated (R-)
Smads are substrates of the TGFβRI kinase, and cytoplasmic
phosphorylation of R-Smads allows for translocation of the
Smad complexes to the nucleus to regulate transcription of
target genes.17
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Previous studies identified mutations in TGFβRI, TGFβRII,
ACTA2, and MYH11 in individuals with FTAA. In most cases,
genetic screenings for mutations in these genes have focused
primarily on patients referred to genetic subspecialists with
either an extensive family history or obvious features of a
complex Mendelian connective tissue disorder, and, therefore,
these patients have an increased likelihood of harboring a
mutation. However, such individuals represent a small subset
of those with genetically mediated TAA. The vast majority of
patients present with limited or unknown family history and
are without evidence of a complex syndromic disorder. These
patients represent diagnostic dilemmas for practicing physicians. This study addresses the potential impact of genetic
testing for these 4 TAA genes on clinical management of
patients with TAA. We determined the frequency of mutations
in these 4 TAA genes in an unbiased population that is more
representative of the population of individuals with genetically mediated TAA seen in cardiovascular clinical practice.

Methods
Patient Cohort Collection
The cohort of patients enrolled in this study consisted of 100 consecutive adult probands from a clinical population with nonsyndromic, potentially genetically triggered aortic aneurysms. Patients with FTAA
were collected from those presenting to cardiologists and cardiothoracic surgeons at Weill Cornell Medical Center. Written informed consent was obtained from all subjects according to a protocol approved
by the institutional review board of Weill Cornell Medical College. To
enroll, subjects needed to have been diagnosed with thoracic aortic
dilation, aneurysm, or dissection and meet at least 1 of these criteria:
1. Age at diagnosis of aortic disease <50 years.
2. Positive family history of aortic aneurysm or dissection in at
least 1 first- or second-degree relative.
3. Features of a connective tissue disorder, such as arachnodactyly, pectus carinatum, or pectus excavatum.
These inclusion criteria were established to represent patients who
might reasonably be clinically suspected to have a genetically mediated disorder. Patients were excluded if they met clinical diagnostic
criteria for Marfan syndrome, LDS, or Ehlers-Danlos syndrome because pathogenesis for these rare syndromes are well known and do
not generally present diagnostic dilemmas to physicians.

DNA Isolation and Mutation Analysis
Blood or saliva samples were obtained from patients. Genomic DNA
was isolated from lymphoblasts separated from whole blood (QIAamp
DNA Blood kit, Qiagen, Valencia, CA) and saliva (Oragene-DNA
kit, DNA Genotek, Kanata, Ontario, Canada) per manufacturer’s instructions. Exons of ACTA2, MYH11, TGFβRI, and TGFβRII were
polymerase chain reaction (PCR) amplified with gene-specific primers from genomic DNA isolated from each patient. Primer sequences
are available on request. Additional mutational analyses of TGFβRII
focused on an alternatively spliced exon, exon 1a that substitutes a 26
amino acid peptide for Val51 in the receptor’s extracellular domain.
This resultant TGFβRII is often referred to as TGFβRIIb, and the specific properties and function of TGFβRIIb are not well documented.18
PCR products were purified by vacuum filtration using a MultiScreenPCR filter plate (Millipore, Darmstadt, Germany) per manufacturer’s
instructions. Purified PCR products were bidirectionally sequenced
and analyzed on an automated sequencer (ABI 3130XL) with BigDye
Terminator v3.1 (Applied Biosystems, Foster City, CA). Exons with
sequence variants were analyzed in family members when available.
In addition, a minimum of 200 control chromosomes from a population of normal samples (mixed-ethnicity unaffected individuals without

known aortic disease) were also analyzed either by restriction fragment
length polymorphism analysis or denaturing high-performance liquid
chromatography on a WAVE Nucleic Acid Fragment Analysis System
(Transgenomic, Omaha, NE). Additional sets of ethnically matched
controls were used as noted in the results section below.
Sequence variants were considered mutations if they (1) caused a
nonsynonymous amino acid change or could potentially alter protein
structure, (2) were absent from a population of at least 200 ethnically
matched control chromosomes, and (3) co-segregated with disease in
the family if family member samples were also available for analysis. In addition, we examined the National Center for Biotechnology
Information (NCBI) single-nucleotide polymorphism (SNP) database
of 4356 chromosomes for ACTA2, MYH11, TGFβRI, and TGFβRII
polymorphisms in genome build 37.3 released in October 2011.

RNA Analyses
Total RNA was isolated from either lymphocytes or homogenized
human aortic tissue using TRIzol reagent (Invitrogen, Grand Island,
NY) per manufacturer’s instructions. RNA was subjected to reverse
transcriptase PCR (RT-PCR; One-Step RT-PCR Kit, Qiagen) to preferentially amplify either the TGFβRII or TGFβRIIb isoform with
exon-specific primers surrounding, or internal to, the alternatively
spliced exon. RT-PCR reactions were performed under the following
conditions: 50oC for 30 minutes (cDNA synthesis), 95oC for 15 minutes (polymerase heat activation), followed by 94oC for 45 seconds,
52oC for 80 seconds, and 72oC for 60 seconds for 35 cycles.

Plasmid Constructs
Full-length cDNAs of both TGFβRII and TGFβRIIb were reverse transcribed as described above from RNA extracted from patient fibroblasts
using primers immediately flanking the coding region of TGFβRII.
RT-PCR products were cloned into the pCR2.1-TOPO vector using the
TOPO TA cloning kit (Invitrogen). Plasmid DNA was isolated (QIAprep
Miniprep kit, Qiagen, La Jolla, CA). The entire coding region of
TGFβRII and TGFβRIIb in each construct was sequenced bidirectionally
in each cDNA construct to confirm the correct full-length sequence for
both. The H56N TGFβRIIb mutation was generated by site-directed mutagenesis (QuikChange Kit, Stratagene, La Jolla CA) per manufacturer’s
instructions. The D40N TGFβRIIb mutation was generated by Overlap
Extension PCR.19 Initial PCR reactions were performed under the following conditions: 95oC for 1 minute, 50oC for 2 minutes, and 72oC for 2
minutes for 25 cycles. PCR products were subjected to gel electrophoresis
and gel purified (QIAquick Gel Extraction Kit, Qiagen) per manufacturer’s instructions. Subsequent PCR reactions were performed using purified DNA from the initial PCR product using the same cycle conditions.
Wild-type TGFβRII as well as wild-type and mutant isoforms
of TGFβRIIb were subcloned into XhoI and BamHI sites of the
pcDNA3.1(-) expression vector 3′ to a cassette encoding a Kozak
sequence to generate TGFβRII- or TGFβRIIb-cDNA3.1. PCR
amplification with XhoI-Kozak-TGFβII-F and BamHI-TGFβRII-R
primers facilitated cloning into pcDNA3.1 (Invitrogen). The entire
coding region of each TGFβRII and TGFβRIIb construct was
bidirectionally sequenced to confirm the correct full-length sequence.

Cell Culture, Transfection, and TGFβ Stimulation
A skin biopsy containing primary dermal fibroblasts from an individual harboring the H56N TGFβRII mutation was cultured in DMEM
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum
and 0.1 mg/mL primocin. Cells were maintained and studied at low passage (passages 2–5). Normal human dermal fibroblasts and L6 rat myoblast cells were obtained from American Type Culture Collection and
grown in DMEM with 10% fetal bovine serum.
Low-passage primary dermal fibroblasts (passages 2–5) were serum starved for 24 hours and then stimulated with 5 ng/mL recombinant human TGFβ1 or recombinant human TGFβ2 (R&D Systems,
Minneapolis, MN) in the presence of 10% serum. After stimulation,
cells were washed twice in cold PBS containing 1 mmol/L Na3VO4
and lysed at 0, 0.5, 1, 2, 4, and 24 hours poststimulation in radioimmunoprecipitation (RIPA) buffer (50 mmol/L Tris HCl pH7.6,
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150 mmol/L NaCl, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1%
SDS) supplemented with protease inhibitors (1X Protease Inhibitor
Cocktail Tablets, Roche, Indianapolis, IN; 1% Ser/Thr Protein
Phosphatase Inhibitor Cocktail, Millipore, Billerica, MA) for subsequent Western blot analysis as described below. Cell stimulation was
performed in triplicate.
One day before transfection, 3×105 L6 cells were plated
and transfected with 500 ng of either wild-type (wt) or mutant
TGFβRII-cDNA3.1 constructs (wt-TGFβRII-, wt-TGFβRIIb-, H56NTGFβRIIb-, or D40N-TGFβRIIb-cDNA3.1) in low serum media using Lipofect AMINE (Invitrogen). Cells either remained unstimulated
or were stimulated with 50 pmol/L TGFβ1 or 50 pmol/L TGFβ2 for
0, 0.5, 1, or 2 hours and lysed as described above in RIPA buffer supplemented with protease inhibitors for Western blot analysis. All cell
transfections and stimulations were performed in triplicate.

SDS-PAGE and Western Blotting
Lysate protein concentrations were determined (CoomassiePlus
Bradford Assay kit, Pierce, Rockford, IL). Twenty micrograms of
cell lysate were electrophoresed on 10% polyacrylamide gels (Pierce)
and transferred to polyvinylidene fluoride membrane (GE Healthcare,
Waukesha, WI). Protein expression was determined by Western blotting with primary antibodies to anti-phosphorylated Smad2 (pSMAD2, Cell Signaling, Danvers, MA) or anti-β-actin. (Sigma, St.
Louis, MO). Bound antibodies were detected by incubation with goat
anti-rabbit secondary antibody (Cell Signaling) followed by chemiluminescence (ECL Plus, GE Healthcare). Densitometry was performed on a BioRad Gel Doc MultiAnalyst system.

Statistical Analysis
All values are expressed as mean±SEM or percentage and 95% confidence intervals for categorical variables. Statistical analyses were
performed using ANOVA and Student t test. P<0.05 was considered
significant. A Sharp-Wilk normality test of our Western blot data

Table.

Description of Cohort

Sex, n
Male

77

Female

23

Ethnicity, n
White

80

White/Hispanic

6

White/Native American

2

Black

2

Black/Hispanic

2

Asian

2

Other

6

Age at enrollment, y
Mean

53

Median

52

Range

21–93

Body surface area (BSA), m2
Mean (n=65)

1.99

Median

2.00

Aortic surgery, n

42

Dissection, n

27

Inclusion criteria, n
Diagnoses <50 y old

64

Connective tissue abnormality

14

Family history

67

revealed that it followed normal distributions with a P≥0.01 and had
equal variance. Binomial power calculations indicate that our power
to detect mutations with a prevalence as low as 1% is 55% in a sample
of 200 control chromosomes and 95% in 588 control chromosomes.
Also, binomial power calculations indicate that our power to detect
NCBI SNPs with a prevalence of 5/4356 chromosomes is 21% in 200
chromosomes and 49% in 588 chromosomes, whereas our detection
power is 37% in 200 chromosomes and 74% in 588 chromosomes
with an SNP having a prevalence of 10/4356 chromosomes.

Results
Patient Cohort
The cohort consisted of predominantly male patients (77 men and
23 women) (Table). This distribution is consistent with previous
studies in which men predominate in a series of clinically
apparent genetically meditated TAAs.1 The majority of patients
were white (80/100), and the remainder were of Hispanic, black,
Native American, or Asian descent. Patients ranged in age from
21 to 93 years of age with an average age of 53. The average
weight of patients was 85.1 kg, and the average height was 177.3
cm with an average body surface area of 2 m2. Of the 100 patients,
64 were diagnosed at <50 years of age. Sixty-seven had a family
history of TAA or thoracic aortic dissection. Only 14 exhibited
connective tissue abnormalities, including joint hypermobility,
pectus excavatum, and pectus carinatum, but none met or nearly
met diagnostic criteria for Marfan or other syndromes.20 At the
time of enrollment, 42 patients had previously undergone aortic
surgery. Aortic dissections had been reported in 27 of the patients.

Aneurysm Gene Mutational Analyses
All patients in this cohort underwent sequencing-based
mutational analyses of the ACTA2, MYH11, TGFβRI, and
TGFβRII genes. Sequencing of the ACTA2 gene revealed 3
missense mutations: T108M, R118Q, and G270E (Figure 1).
Two intronic polymorphisms were seen; however, no exonic
polymorphisms were detected. The R118Q mutation in family
JNW has been previously reported in 2 other TAA families.21
T108M and G270E were not found in 200 white/Northern
European control chromosomes. All 3 affected probands had
TAAs, 2 of which led to acute dissections, and all required
surgery. Both the R118Q (family JNW) and G270E (family
ANS) mutations co-segregated with disease in families. Family members of SY92, who carried the T108M mutation, were
unavailable for genetic analysis. Patient SY92 also had an
atrial septal defect and patent ductus arteriosus (PDA). None
of the ACTA2 mutations was found in the NCBI SNP database.
Three mutations and 13 polymorphisms were identified in
the MYH11 gene (Figure 2), including 2 missense mutations
(R1590Q and E1899D) and 1 splice site alteration: a 7 nucleotide substitution located 5 base pairs 3′ to exon 27. None of
the variants was detected in 200 white/Northern European
control chromosomes. The mutations co-segregated with aortic disease in families JNE and ANHH. Family members of
patient ANO II-2 (carrying a 7 nucleotide substitution located
5 base pairs 3′ to exon 27) were unavailable for genetic analysis. Individual ANHH II-2 exhibited TAAs and also a bicuspid
aortic valve; however, ANO II-2 had a tricuspid aortic valve.
Individual JNE II-1 exhibited TAA, resulting in 2 dissections.
None of these mutations was identified in the NCBI SNP database except for E1899D MYH11 that was found in 10/4356
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Figure 1. Mutational analysis of ACTA2 in
families ANS, JNW, and SY92. A, Automated
sequence analyses of ACTA2 from affected
individuals in families ANS, JNW, and SY92 are
shown. A 1-bp deletion in families ANS, JNW,
and SY92 (arrow) generates a missense mutation
indicated by the amino acid code. B, Pedigrees
of families ANS, JNW, and SY92 with an ACTA2
mutation indicate that mutations co-segregate
with disease. Mutations are present only in family
members affected with thoracic aortic aneurysm.
Arrow indicates family proband. N/A indicates
not applicable.

chromosomes corresponding to a frequency of 0.23%. The
significance of this polymorphism is unknown given that the
NCBI database includes patients with cardiovascular disease
whose aortic aneurysm status is unknown. In our study, we

screened 200 chromosomes from control patients who were
unaffected individuals without known aortic disease.
Members of the cohort were also screened for mutations
in both TGFβR type I and type II genes, TGFβRI and

Figure 2. Mutational analysis of myosin heavy
chain 11 (MYH11) in families JNE, ANHH, and ANO.
A, Automated sequence analyses of MYH11 from
affected individuals in families JNE, ANHH, and
ANO are shown. A 1-bp deletion in families JNE
and ANHH (arrow) generates a missense mutation
indicated by the amino acid code. A 7-bp intronic
substitution in family ANO (arrow) produces a
splice site alteration located at the nucleotide position relative to the preceding exon. B, Pedigrees
of families JNE, ANHH, and ANO are shown and
indicate that MYH11 mutations co-segregate with
disease. Mutations are present only in family members affected with thoracic aortic aneurysm. Arrow
indicates family proband.
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Figure 3. Transforming growth factor TGFβRII
and TGFβRIIb mutations in families KNA, ANV,
and KNK. A, Automated sequence analyses of
TGFβRII and TGFβRIIb from affected individuals in families KNA, ANV, and KNK are shown.
A 1-bp deletion in families KNA, ANV, and KNK
(arrow) generates a missense mutation indicated
by the amino acid code. B, Pedigree of family
KNA with a TGFβRII mutation and families ANV
and KNK with TGFβRIIb mutations indicate that
mutations co-segregate with disease. Mutations
are present only in family members affected with
thoracic aortic aneurysm. Arrow indicates family
proband.

TGFβRII. In TGFβRI, 3 exonic polymorphisms and no
mutations were found. Two exonic polymorphisms and 1
mutation were detected in TGFβRII (Figure 3). The TGFβRII
missense mutation (A414T) in patient KNA II-2 is located
in the protein’s kinase domain, co-segregates with disease
in the family, and was absent in 206 ethnically matched
(Ashkenazi Jewish) control chromosomes. All 4 family
members carrying the mutation were diagnosed with aortic
aneurysm. Three of the 4 also have pectus excavatum, one of
whom was also diagnosed with an ostium secundum atrial
septal defect. There was no evidence of other LDS features
such as vascular tortuosity or bifid uvula in probands or
family members. This TGFβRII mutation was not found in
the NCBI SNP database.
TGFβRII has an additional alternatively spliced isoform
containing a 75 base pair exon (exon 1a) in its extracellular domain that produces TGFβRIIb. TGFβRII exon 1a was
also sequenced in all 100 individuals. No polymorphisms
were found in exon 1a, but 2 missense mutations were identified. The D40N mutation (family KNK) was not detected
in 224 white/Northern European control chromosomes. The
H56N mutation (family ANV) co-segregated with disease in
the family and was absent from 588 control chromosomes
including 384 ethnically matched (Ashkenazi Jewish) chromosomes. KNK II-1 had a TAA and also a bicuspid aortic
valve. ANV II-1 had an aortic aneurysm and pectus carinatum. H56N was not found in the NCBI SNP database, but
D40N TGFβRIIb, identified in patient KNKII-1 for which
we were unable to determine co-segregation with disease,
was found in 5/4356 chromosomes corresponding to a frequency of 0.11%. The significance of this polymorphism
is unknown given that the NCBI database includes patients

with cardiovascular disease whose aortic aneurysm status is
unknown. In our study, we screened 224 chromosomes from
control patients who were unaffected individuals without
known aortic disease.
In total, 9 of 100 probands were found to have a mutation
in 1 of the 4 genes analyzed. No genotype-phenotype correlations were observed among the probands’ available family members, and mutations within the same gene did not
necessarily correspond to any specific phenotypic variation.
Families ANV, KNK, and KNA each have TGFβRII mutations yet exhibit considerable interfamilial variation. Four of
the 7 individuals with a TGFβRII mutation (including those
with a mutation in the alternatively spliced exon) exhibited
noncardiovascular connective tissue abnormality. Two were
diagnosed with a congenital heart defect.
Although MYH11 mutations have been previously associated with PDA,9 none of the individuals with MYH11 mutations detected in the current study was known to have PDA.
Livedo reticularis or iris flocculi were not observed in individuals in this study with ACTA2 mutations.

TGFβRII Expression and Activity
Previous studies22 established that TGFβR kinase domain
mutations inactivate the receptor, although downstream TGFβ
signaling is paradoxically increased. Similarly, we identified
the A414T TGFβRII mutation in a patient and examined its
kinase activity through in vitro expression of A414T-TGFβRII
in a luciferase vector. Mutant TGFβRII was inactive (data not
shown). In this study, we sought to understand how the novel
TGFβRIIb mutations we observed outside of the TGFβRII
kinase domain might alter TGFβ signaling. Tissue expression patterns of TGFβRII alternative splicing have not been
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Figure 4. mRNA expression of TGFβRII isoforms in aortic tissue and lymphocytes. RT-PCR performed using various pairs
of TGFβRII and TGFβRIIb isoform specific primers to amplify
exons 1, 1a, 2, and 3 (a), exons 1, 2, and 3 (b), and exons 1a, 2,
and 3 (c) from isolated human aortic tissue (lanes 1–2) and lymphocyte (lanes 3–4) RNA.

established. Using RT-PCR, we determined that both spliced
isoforms, TGFβRII and TGFβRIIb, are expressed in the human
aortic wall and lymphocytes (Figure 4) and also in cultured dermal fibroblasts and aortic smooth muscle cells (not shown).
To determine the effects of mutant TGFβRIIb on TGFβ
signaling, we compared relative levels of TGFβ1 and TGFβ2
signaling (indicated by pSMAD2 levels) in normal dermal
fibroblasts with dermal fibroblasts isolated from individual ANV I-1 who is heterozygous for the H56N TGFβRIIb
mutation (Figure 5). Although the specific contributions of
canonical TGFβ signaling via Smads versus noncanonical TGFβ signaling via extracellular signal-regulated kinase
mitogen-activated protein kinase (MEK/ERK) pathways to
the pathogenesis of specific aneurysm and aneurysm related
phenotypes remain under active investigation,23–25 pSMAD2
provides a valuable biomarker of TGFβ activity.26 On TGFβ1
stimulation of normal dermal fibroblasts, we observed an
increase in pSMAD2 levels peaking at 0.5 hours poststimulation before declining by 4 hours. By contrast, TGFβ1 stimulation of ANV I-1 dermal fibroblasts resulted in delayed
SMAD2 phosphorylation that peaked at 2 hours. On stimulation with TGFβ2, normal dermal fibroblasts exhibited similar

kinetics to TGFβ1 stimulation; pSMAD2 levels peaked at
0.5 hours, although high levels of pSMAD2 persisted even 4
hours poststimulation. TGFβ2 stimulation of ANV I-1 dermal
fibroblasts exhibited distinct kinetics of SMAD2 phosphorylation. Although pSMAD2 levels peaked at 0.5 hours, these
levels rapidly declined by 1 hour and were markedly reduced
at all time points compared with normal dermal fibroblasts.
Because dermal fibroblasts from individual ANV I-1 express
both wt- and mutant TGFβRIIb isoforms, one cannot distinguish
the activities of each isoform in these cells. Therefore, we utilized
L6 rat myoblast cells lacking both endogenous TGFβRIIb and
TGFβRIII to compare TGFβ signaling activities in wt- and
mutant TGFβRIIb. L6 myoblasts were transfected with constructs
encoding wt-TGFβRII, wt-TGFβRIIb, H56N-TGFβRIIb, or
D40N-TGFβRIIb and then stimulated with 50 pmol/L TGFβ1
or TGFβ2. Our preliminary examination of pSMAD2 levels
measured during the first 2 hours poststimulation showed that
TGFβRII activity peaked at 0.5 hours in TGFβ1-stimulated L6
cells, whereas it peaked at 1 hour in TGFβ2-stimulated cells.
Therefore, in subsequent studies, we assessed peak TGFβ receptor
activity in genetically engineered L6 cells after stimulation with
either TGFβ1 for 0.5 hours (Figure 6) or TGFβ2 for 1 hour
(Figure 7). L6 cells transfected with either wt-TGFβRII or
wt-TGFβRIIb exhibited comparable responsiveness to TGFβ1
(Figure 6A, n=3). Similarly, introduction of neither H56NTGFβRIIb nor D40N-TGFβRIIb significantly modified TGFβ1
responsiveness (Figure 6B, n=3). However, when cells were
stimulated with TGFβ2 (Figure 7), pSmad2 levels were reduced
by 74% in cells transfected with wt-TGFβRIIb compared with
those transfected with wt-TGFβRII (Figure 7A; n=3, P=0.02).
Introduction of either H56N-TGFβRIIb or D40N-TGFβRIIb,
then, ablated this reduction in receptor activity, and both
resulted in a nearly 3-fold increase in pSmad2 levels (Figure 7B;
n=3, P=0.009 and P=0.02, respectively).

Discussion

Figure 5. TGFβ1 and TGFβ2 signaling in dermal fibroblasts.
A and B, Cultured fibroblasts were isolated from normal patient
with wild type (wt)-TGFβRII and ANVI-1 patient with H56NTGFβRIIb mutation. Representative Western blot analyses
shown for pSMAD2 protein expression in wt-TGFβRII or H56NTGFβRIIb fibroblasts stimulated with either TGFβ1 (A) or TGFβ2
(B) for indicated time points. Corresponding β-actin blots shown.
A, H56N-TGFβRIIb dermal fibroblasts exhibit delayed TGFβ1
signaling compared with normal dermal fibroblasts. B, H56NTGFβRIIb dermal fibroblasts exhibit decreased TGFβ2 signaling
compared with normal dermal fibroblasts.

FTAA is a clinically heterogeneous disorder exhibiting variation in both age of onset and degree of aortic dilatation prior
to dissection. FTAA can be part of a complex syndrome, such
as LDS, or an isolated finding. The 4 genes analyzed in this
study (ACTA2, MYH11, TGFβRI, and TGFβRII) were initially
identified as associated with syndromic FTAA, and the cause
of FTAA in many families remains unknown. The utility of
mutational analyses in clinical strategies for an isolated FTAA
diagnostic workup is unclear.
The principal goal of our study was to address the potential
value of clinical genetic testing of ACTA2, MYH11, TGFβRI,
and TGFβRII in nonsyndromic FTAA to improve patient care
and diagnosis. Although these 4 FTAA-causative genes are
known to be prevalent in cohorts ascertained for molecular
genetic studies, their contribution to disease in a population
relevant to clinical practice has not previously been studied.
In this study, we determined the frequency of mutations in
these 4 TAA genes in a cohort routinely seen in cardiology
clinical practice. Individuals diagnosed with known Marfan
syndrome, LDS, or Ehlers-Danlos syndrome were excluded.
In this study, 9% of patients had a mutation in 1 of the genes
analyzed. Three percent of patients had mutations in ACTA2,
3% in MYH11, and 3% in TGFβRII. No mutations were found
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Figure 6. In vitro TGFβ1 stimulation does not alter TGFβRII and
TGFβRIIb activity. A, Relative quantification of pSmad2 expression after in vitro TGFβ1 stimulation. Bar graph displays densitometric quantification of pSmad2 protein expression relative
to β-actin in untransfected control, wild-type (wt)-TGFβRII and
wt-TGFβRIIb L6 cells (n=3). No significant change in TGFβRII
or TGFβRIIb activity compared with control cells. B, Relative
quantification of pSmad2 expression after in vitro TGFβ1 stimulation. Bar graph displays densitometric quantification of pSmad2
relative to β-actin in control wt-TGFβRIIb, H56N-TGFβRIIb, and
D40N-TGFβRIIb L6 cells (n=3). No significant change in activity
in mutant TGFβRIIb cells compared with wt-TGFβRIIb cells in
response to 0.5 hour 50 pmol/L TGFβ1 stimulation. Values normalized to control L6 cells. All data presented as mean±SEM. P
values shown. NS indicates not significant.

in TGFβRI, consistent with the reported rarity of TGFβRI
mutations outside of LDS.27–29
Previous studies reported higher rates of mutation (14%
in ACTA2 and 5%–10% in TGFβRII) than observed here on
screening the same genes.9,10,30 Our study differs from those
studies whose cohorts may have been ascertained through
family-based programs and medical genetic clinics to which
patients are largely referred if they are believed to have signs
or symptoms of known disorders, such as LDS, Marfan syndrome, and Ehlers-Danlos syndrome. Patients in those studies
are more likely to harbor a mutation in one of these genes, and
our cohort may be more representative of the patient population routinely presenting to cardiovascular clinical practices.
Our study provides an estimate of the potential value of
genetic testing for mutations in known aortic aneurysm disease
genes as part of the diagnostic workup of these patients who are
often seen by the general cardiologist or cardiothoracic surgeon.

Figure 7. In vitro TGFβ2 stimulation alters TGFβR2 and TGFβRIIb
activity. A, Relative quantification of pSmad2 expression after
in vitro TGFβ2 stimulation. Bar graph displays densitometric
quantification of pSmad2 protein expression relative to β-actin in
untransfected control, wild-type (wt)-TGFβRII and wt-TGFβRIIb
L6 cells (n=3). wt-TGFβRIIb cells exhibit decreased TGFβ2 signaling compared with wt-TGFβR2 cells. B, Relative quantification of pSmad2 expression after in vitro TGFβ2 stimulation. Bar
graph displays densitometric quantification of pSmad2 relative
to β-actin in control wt-TGFβRIIb, H56N-TGFβRIIb, and D40NTGFβRIIb L6 cells (n=3). Mutant TGFβRIIb cells exhibit increased
response after 1 hour 50 pmol/L TGFβ2 stimulation compared
with wt-TGFβRIIb cells. Values normalized to control L6 cells. All
data presented as mean±SEM. P values shown.

The 95% confidence interval for the point estimate of 9% in
our population is consistent with finding a potentially causative
mutation in 5% to 16% of such patients in cardiovascular clinical
practices. Genetic testing can be a valuable adjunct for diagnostic
management of aortic aneurysm because this disorder often goes
undiagnosed until a dissection or rupture occurs. Individuals
identified by genetic testing as at risk for aortic aneurysm
development can undergo interval imaging earlier to monitor the
progression of aortic dilation and to facilitate intervention prior
to rupture and dissection. This study provides a foundation for
future studies that will likely provide insight into how enhanced
diagnostic algorithms incorporating routine TAA genetic testing
can improve patient outcomes and survival. Regardless, our study
critically highlights the need for further FTAA gene identification
because most genetically triggered aortic aneurysm patients
in our study had no evidence of mutation in any of the genes
analyzed. With clinical deployment of exonic and genomewide
sequencing that do not rely on family-based analyses, cohorts
such as the one followed here will provide a rich source for such
gene identification.
Although no genotype-phenotype correlation was found
in this study, the statistical power to detect correlations may
have been inadequate because of the small number of individuals with a mutation. Nonetheless, the study already highlights certain clinical diagnostic hazards. For instance, PDA
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has been strongly associated with MYH11 mutations in fact,
although we observed PDA in the setting of ACTA2 mutations
as well. Thus, the presence of PDA should not provoke the
presumption of MYH11 mutations.
TGFβ signaling has become an emerging target for novel
therapies for aortic aneurysms. Previous studies have established that dysregulated TGFβ signaling contributes to aortic
aneurysms.22,31 However, a paradox in the mode of pathogenesis
obfuscates a clear functional role for TGFβ in aneurysm development.16 Identification of TGFβR mutations in LDS and characterization of novel TGFβRIIb mutations in an alternatively
spliced gene segment in our study highlight the contribution of
enhanced TGFβ signaling to FTAA. Although previously identified TGFβR mutations modified the receptors’ kinase domain,
this study identifies novel mutations in an alternatively spliced
segment of TGFβRII that is not involved in kinase activity.
Functional analyses of several kinase domain mutations have
revealed consequent loss-of-function that nevertheless displayed a paradoxical enhancement of TGFβ signaling in patient
aortic tissue. By contrast, mutations in the alternatively spliced
segment of TGFβRIIb described here are unique because they
augment receptor activity, and these findings prompted us to
evaluate the biochemical significance of these mutations.
Prior mutational analyses of TGFβRII have rarely included
the alternatively spliced segment.9,27 Little is known about the
function of this alternative receptor isoform.32,33 A previous study
asserted that TGFβRII requires an accessory receptor, TGFβRIII,
for efficient binding of TGFβ2 and subsequent signaling.34
Rotzer et al33 proposed that TGFβRIIb alone is capable of binding TGFβ1, TGFβ2, and TGFβ3 whereas del Re et al32 suggested that TGFβRIIb alone is capable of binding only TGFβ1
and TGFβ3. In contrast to the binding data, del Re et al32 further proposed that TGFβRIIb mediates in vitro TGFβ2 signaling
in a dose-dependent manner. We demonstrate that the segment
encoded by exon 1a does not alter receptor function on stimulation with TGFβ1, but does alter TGFβ2 signaling. TGFβRIIb has
a lower TGFβ2-stimulated activity than TGFβRII, and mutations
in this alternatively spliced segment reverse this effect, increasing
receptor activity levels similar to that of prototypical TGFβRII.
We then propose that TGFβRIIb expression is a regulatory mechanism for TGFβ2 signal transduction, and dysregulation of the
TGFβ2 signaling pathway resulting from TGFβRIIb mutations
can contribute to aneurysm pathogenesis.
Regulation of the TGFβ signaling pathway is important in
determining cellular outcome, and the underlying mechanisms
are complex. This pathway depends on several factors including
the stoichiometric balance of TGFβ ligands and receptors
expressed within the cell. Although TGFβRIIb binds TGFβ1,32,33
we did not observe a change in TGFβI signaling in response to
mutant TGFβRIIb expression. On TGFβ2 stimulation of cells
expressing either wt-TGFβRII or wt-TGFβRIIb, we observed
significantly less TGFβRIIb activity relative to TGFβRII activity.
However, mutant TGFβRIIb isoforms ablated this reduction in
receptor activity by increasing TGFβ2-stimulated TGFβRIIb
activity to levels equivalent to that of wt-TGFβRII. The increase
in TGFβ2 signaling that we observe may be related to complex
stoichiometric interactions at the cell surface between TGFβ
ligands and various TGFβRII isoforms as suggested by del Re
et al.32 The precise mechanism whereby TGFβ ligand binding

may induce receptor activation is conflicting. Some models
propose that TGFβ ligands bind TGFβRII dimers that recruit
TGFβRI dimers to form a heterotetrameric signaling complex.35
Other models, which propose the existence of inactive preformed
complexes of TGFβRI and TGFβRII dimers,36,37 are supported
by potential cooperative TGFβ2 ligand binding to a TGFβRITGFβRIIb complex in which the receptors make physical
contact.32 Krishnaveni et al38 suggest that TGFβRIIb favors
heterodimerization with TGFβRII because this interaction
is more robust. Overall, these data suggest a complex TGFβ
signaling process further depending on the stoichiometric
interactions between TGFβ ligands and various receptor
isoforms. Further investigation in vivo of these interactions will
add to our understanding of aortic aneurysm pathogenesis.
Aberrant TGFβ signaling that results from type I and II
receptor mutations has been implicated in the pathogenesis
of cardiovascular disorders involving TAAs. We showed that
TGFβ2 signaling is decreased in cells expressing TGFβRIIb,
and mutations in this receptor result in increased TGFβ2 signaling. Identification of TGFβRIIb activating mutations in 2
TAA patients supports the hypothesis that an increase in TGFβ
signaling contributes to aortic pathogenesis. Furthermore, this
evidence highlights the scientific and clinical import of expanding diagnostic strategies to include the alternative segment of
TGFβRIIb in genetic screening of individuals with TAA. Taken
together, these findings suggest that TGFβRIIb expression is
likely an important regulatory mechanism of TGFβ2 signaling in the aorta, and there may be differential contributions of
TGFβ1 and TGFβ2 signaling to aneurysm pathogenesis.
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CLINICAL PERSPECTIVE
Thoracic aortic aneurysm (TAA) is a common progressive disorder involving gradual dilation of the ascending and/or
descending thoracic aorta that is clinically unsuspected until potentially lethal aortic dissection or rupture. TAA is often part
of a complex connective tissue syndrome such as Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes, but nonsyndromic
TAAs also occur as genetically triggered inherited disorders. Genetically triggered TAAs account for ≈20% of TAAs. Prior
analyses of familial TAA in research cohorts have identified disease-causing mutations in genes encoding myosin heavy
chain 11 (MYH11), α-smooth muscle actin (ACTA2), and transforming growth β receptors I and II (TGFβRI and TGFβRII).
Mutational analyses of these 4 genes were now performed in a cohort of patients routinely presenting to cardiovascular clinics
and suspected to have genetically mediated nonsyndromic aortic disease. Nine percent of patients had a mutation in one of
the 4 genes analyzed. Three percent of patients had mutations in ACTA2, 3% in MYH11, and 3% in TGFβRII. TGFβRII mutations included ones identified in an alternatively spliced TGFβRII exon, exon 1a, that encodes the TGFβRIIb isoform. These
TGFβRII exon 1a mutations occurred in 2% of these TAA patients and suggest that altered TGFβ2 signaling contributes to
aneurysm pathogenesis. This study’s findings support the potential value to cardiovascular practitioners of genetic testing
with a multigene aortic disease gene panel in the diagnostic workup of TAA patients.

